Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization
Prostate-Specific Membrane Antigen (PSMA) is an established biomarker for the imaging and experimental therapy of prostate cancer (PCa), as it is strongly upregulated in high-grade primary, androgen-independent, and metastatic lesions. Here, we report on the development and functional characterization of recombinant single-chain Fv (scFv) and Fab fragments derived from the 5D3 PSMA-specific monoclonal antibody (mAb). These fragments were engineered, heterologously expressed in insect S2 cells, and purified to homogeneity with yields up to 20 mg/L. In vitro assays including ELISA, immunofluorescence and flow cytometry, revealed that the fragments retain the nanomolar affinity and single target specificity of the parent 5D3 antibody. Importantly, using a murine xenograft model of PCa, we verified the suitability of fluorescently labeled fragments for in vivo imaging of PSMA-positive tumors and compared their pharmacokinetics and tissue distribution to the parent mAb. Collectively, our data provide an experimental basis for the further development of 5D3 recombinant fragments for future clinical use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 21(2020), 18 vom: 12. Sept. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Novakova, Zora [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.02.2021 Date Revised 07.05.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms21186672 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315044977 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315044977 | ||
| 003 | DE-627 | ||
| 005 | 20231225154047.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms21186672 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315044977 | ||
| 035 | |a (NLM)32932591 | ||
| 035 | |a (PII)E6672 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Novakova, Zora |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Engineered Fragments of the PSMA-Specific 5D3 Antibody and Their Functional Characterization |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.02.2021 | ||
| 500 | |a Date Revised 07.05.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Prostate-Specific Membrane Antigen (PSMA) is an established biomarker for the imaging and experimental therapy of prostate cancer (PCa), as it is strongly upregulated in high-grade primary, androgen-independent, and metastatic lesions. Here, we report on the development and functional characterization of recombinant single-chain Fv (scFv) and Fab fragments derived from the 5D3 PSMA-specific monoclonal antibody (mAb). These fragments were engineered, heterologously expressed in insect S2 cells, and purified to homogeneity with yields up to 20 mg/L. In vitro assays including ELISA, immunofluorescence and flow cytometry, revealed that the fragments retain the nanomolar affinity and single target specificity of the parent 5D3 antibody. Importantly, using a murine xenograft model of PCa, we verified the suitability of fluorescently labeled fragments for in vivo imaging of PSMA-positive tumors and compared their pharmacokinetics and tissue distribution to the parent mAb. Collectively, our data provide an experimental basis for the further development of 5D3 recombinant fragments for future clinical use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a NAALADase | |
| 650 | 4 | |a antibody fragment | |
| 650 | 4 | |a glutamate carboxypeptidase II | |
| 650 | 4 | |a in vivo imaging | |
| 650 | 4 | |a monoclonal antibody | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a prostate-specific membrane antigen | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antigens, Surface |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Single-Chain Antibodies |2 NLM | |
| 650 | 7 | |a FOLH1 protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.17.21 |2 NLM | |
| 650 | 7 | |a Glutamate Carboxypeptidase II |2 NLM | |
| 650 | 7 | |a EC 3.4.17.21 |2 NLM | |
| 700 | 1 | |a Belousova, Nikola |e verfasserin |4 aut | |
| 700 | 1 | |a Foss, Catherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Havlinova, Barbora |e verfasserin |4 aut | |
| 700 | 1 | |a Gresova, Marketa |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Gargi |e verfasserin |4 aut | |
| 700 | 1 | |a Lisok, Ala |e verfasserin |4 aut | |
| 700 | 1 | |a Prada, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Barinkova, Marketa |e verfasserin |4 aut | |
| 700 | 1 | |a Hubalek, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Pomper, Martin G |e verfasserin |4 aut | |
| 700 | 1 | |a Barinka, Cyril |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 21(2020), 18 vom: 12. Sept. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2020 |g number:18 |g day:12 |g month:09 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms21186672 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2020 |e 18 |b 12 |c 09 | ||